$Portage Biotech(PRTG)$ the Board of Directors has made the decision to pause further enrollment in the ADPORT-601 clinical trial of PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor).
| 发布于: | 雪球 | 转发：0 | 回复：0 | 喜欢：0 |
$Portage Biotech(PRTG)$ the Board of Directors has made the decision to pause further enrollment in the ADPORT-601 clinical trial of PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor).